1.1 Controls
for the Prevention And Detection Of Fraudulent Or Abusive Practices
The contractor shall establish procedures
and utilize controls for the prevention and detection of fraudulent
or abusive patterns and trends in billings by providers, pharmacies,
entities, and beneficiaries on a pre- and postpayment basis. Controls
shall include the following (and be made available to the Defense
Health Agency (DHA) Program Integrity Office (PI)):
• Eligibility verifications for beneficiaries
and providers/pharmacies.
• Coordination of benefits.
• Prepayment edits (e.g., applied to program
exclusions and limitations).
• Utilization of discretionary or coordinated
placement of providers/beneficiaries on prepayment review.
• Postpayment utilization review to detect
fraud and/or abuse by either beneficiaries, pharmacies, or providers
and to establish dollar loss to the Government.
• Application of security measures to protect
against embezzlement or other dishonest acts by employees.
• Incorporate anti-fraud attestation language
whenever/wherever practical (e.g., claim forms, network agreements,
electronic claims submission agreements).
• Utilization of Fraudlines/Hotlines.
• Prepayment duplicate screening.
• Postpayment duplicate screening.
• Verification of provider status (e.g.,
credentials, licensure) to include appropriate termination action
when findings/recommendations of boards, etc. results in loss or suspension
of licensure or certification.
• Program Integrity (PI) targeted measures
(e.g., prepay anti-fraud review; use of post payment fraud detection
software; routine anti-fraud data mining; investigative anti-fraud auditing;
select provider/beneficiary education).
• Specific to pharmacy, controls include
comparing reversal rates; excessive partial fill submissions; high
use patients; review of outliers; codes with medication therapy
for high ingredient costs; claims with high average ingredient cost;
review of brand/generic fill rates; top pharmacies per generic code
rate; controlled substance prescription rates; and ability to conduct
on-site audits of pharmacies who meet these indicators and ability
to review/perform on-site of top one percent of providers who meet
these indicators.